Antiepileptic drugs in obesity, psychotropic-associated weight gain, and eating disorders

Antiepileptic Drugs to Treat Psychiatric Disorders

Volumn , Issue , 2008, Pages 283-309

  McElroy, Susan L ^a,b   Guerdjikova, Anna I ^a,b   Keck, Paul E ^a,b   Pope, Harrison G ^c,d   Hudson, James I ^c,d  

^a LINDNER CENTER OF HOPE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349228594     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849382666-19     Document Type: Chapter

References (191)

1. National Institutes of Health (National Heart, Lung, and Blood Institute): Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. The Evidence Report. Bethesda, MD: National Institutes of Health, 1998.
2. Bray GA, Bouchard C, eds. Handbook of Obesity. Etiology and Pathophysiology, 2nd ed. New York, NY: Marcel Dekker, 2004.
3. Bray GA. Obesity: the disease. J Med Chem 2006; 49:4001-4007.
4. Hensrud DD, Klein S. Extreme obesity: a new medical crisis in the United States. Mayo Clin Proc 2006; 81(10 suppl):S5-S10.
5. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295:1549-1555.
6. Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health 2007; 121: 492-496.
7. Friedman JM. A war on obesity, not the obese. Science 2003; 299:856-858.
8. Friedman JM. Modern science versus the stigma of obesity. Nat Med 2004;10:563-569.
9. Van Gaal LF, Mertens IL, DeBlock CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444:875-880.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
11. McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004; 65:634-651.
12. Bornstein SR, Schuppenies A, Wong M-L, et al. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene-environment interactions. Mol Psychiatry 2006; 11:892-902.
13. Black DW, Goldstein RB, Mason EE. Prevalence of mental disorders in 88 morbidly obese bariatric clinic patients. Am J Psychiatry 1992; 149:227-234.
14. McElroy SL, Allison DA, Bray GA, eds. Obesity and Mental Disorders. New York, NY: Taylor & Francis Group, 2006.
15. Onyike CU, Crum RM, Lee HB, et al. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2003; 158:1139-1147.
16. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 2006; 63:824-830.
17. McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry 2006; 51:274-280.
18. Hudson JI, Lalonde JK, Berry JM, et al. Binge eating disorder as a distinct familial phenotype in obese individuals. Arch Gen Psychiatry 2006; 63:313-319.
19. Hudson JI, Hiripi E, Pope HG Jr., et al. The prevalence and correlates of eating disorders in the national comorbidity survey replication. Biol Psychiatry 2006, 61, 348-358.
20. Volkow ND, O’Brien CP. Issues for DSM-V: should obesity be included as a brain disorder? Am J Psychiatry 2007; 164:708-710.
21. Devlin MJ. Is there a place for obesity in DSM-V? Int J Eat Disord 2007; 40(suppl): S83-S88 (comment in Int J Eat Disord 2007; 40 (suppl):S104-S106; Int J Eat Disord 2007; 40(suppl):S107-S110).
22. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142:532-546.
23. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005; 65: 1391-1418.
24. Hofbauer KG, Nicholson JR, Boss O. The obesity epidemic: current and future pharmacological treatments. Ann Rev Pharmacol Toxicol 2007; 47:565-592.
25. Haddock CK, Poston WS, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26:262-273.
26. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonobant. Lancet 2007; 369:71-77.
27. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006; (4):CD006162.
28. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf. Accessed June 25, 2007.
29. Appolinario JC, Bueno JR, Coutinho W. Psychotropic drugs in the treatment of obesity: what promise? CNS Drugs 2004; 18:629-651.
30. Gadde KM, Xiong GL. Buproprion for weight reduction. Expert Rev Neurother 2007; 7: 17-24.
31. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, doseranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11:722-733.
32. Wilding J, Gaal L, Rissanen A, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004; 28:1399-1410.
33. Astrup A, Caterson I, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004; 12:1658-1669.
34. Tonstad S, Tykarski A, Weissgarten J, et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 2005; 96:243-251.
35. Tremblay A, Chaput J-P, Berube S, et al. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol 2007; 63:123-134.
36. Toplak H, Hamann A, Moore R, et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obesity 2007; 31:138-146.
37. Elisasson B, Gudbjornsdottir S, Cederholm J, et al. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes 2007; 31:1140-1147.
38. Rosenstock J, Hollander P, Gadde KM, et al. A randomized, double-blind, placebocontrolled multicenter study to assess the efficacy and safety of topiramate controlled-release in the treatment of obese, type 2 diabetic patients. Diabetes Care 2007; 30:1480-1486.
39. Stenlof K, Rossner S, Vercruysse F, et al. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab 2007; 9:360-368.
40. Gadde KM, Franciscy DM, Wagner HR II, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289:1820-1825.
41. Orexigen. Products. Available at: http://www.orexigen.com/products/products14/. Accessed June 22, 2007.
42. Meredith CH. A single-center, double-blind, placebo-controlled evaluation of lamo-trigine in the treatment of obesity in adults. J Clin Psychiatry 2006; 67(2):258-262.
43. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003; 17:781-791.
44. Gadde KM, Yonish GM, Foust MS, et al. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry 2007; 68:1226-1229.
45. Pellock JM, Faught E, Leppik IE, et al. Felbamate: consensus of current clinical experience. Epilepsy Res 2006; 71:89-101.
46. Hadjikoutis S, Pickersgill TP, Smith PE. Drug points: weight loss associated with lev-etiracetam. BMJ 2003; 327:905.
47. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001; 24:969-978.
48. Hamandi K, Sander JW. Pregbalin: a new antiepileptic drug for refractory epilepsy. Seizure 2006; 15:73-78.
49. Prabhakar S, Sahota P, Kharbanda PS, et al. Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study. Epilepsia 2007; 48:1371-1377.
50. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696.
51. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry 2003; 64(suppl 8):22-29.
52. Keck PE Jr., McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry 2003; 64:1426-1435.
53. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65:267-272.
54. Baptista T, Zarate J, Joober R, et al. Drug-induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004; 5:279-299.
55. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain. A literature analysis. Drug Safety 2006; 29:303-319.
56. McIntyre RS, Soczynska JK, Bordbar K, et al. Antipsychotic-associated weight gain. In: Bermudes RA, Keck PE Jr., McElroy SL, eds. Managing Metabolic Abnormalities in the Psychiatrically III. A Clinical Guide for Psychiatrists. Washington, DC: American Psychiatric Publishing, 2007,165-201.
57. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334-1349.
58. Bermudes RA, Keck PE Jr., McElroy SL. Metabolic risk assessment, monitoring, and interventions. Translating what we have learned into practice. In: Bermudes RA, Keck PE Jr., McElroy SL, eds. Managing Metabolic Abnormalities in the Psychiatrically III. A Clinical Guide for Psychiatrists. Washington, DC: American Psychiatric Publishing, 2007, 277-302.
59. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry developing products for weight management. Revised February 2007. Available at: http://www.fda.gov/cder/guidance/index.htm.
60. Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006; 7:863-887.
61. Thiesen FM, Linden A, Geller F, et al. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Trans 2003; 110:111-121.
62. Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry 2006; 163:1199-1201.
63. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007; (1):CD005148.
64. Klein DJ, Cottingham EM, Sorter M, et al. A randomized, double-blind, placebocontrolled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 153: 2072-2079.
65. Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007; 93:99-108.
66. Ko YH, Joe SH, Jung IK, et al. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005; 28:169-175.
67. Nickel MK, Nickel CN, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women. A random, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005; 25:211-217.
68. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 2006; 82:115-117.
69. Roy Chengappa KN, Schwarzman LK, Hulihan JF, et al. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebocontrolled trial. J Clin Psychiatry 2006; 67:1698-1706.
70. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002; 4:207-213.
71. McElroy SL, Frye MA, Altshuler LL, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord 2007; 9:426-434.
72. Vieta E, Goikolea JM, Olivares JM, et al. 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. J Clin Psychiatry 2003; 64:834-839.
73. Vieta E, Sanchez-Moreno J, Goikolea JM, et al. Effects on weight and outcome of longterm olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psy-chopharmacol 2004; 24:374-378.
74. Bahk WM, Shin YC, Woo J, et al. Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:115-121.
75. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47:1025-1033.
76. Chengappa KN, Levine J, Rathore D, et al: Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case series. Eur Psychiatry 2001; 16:186-190.
77. Dursun SM, Devarajan S. Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action? Can J Psychiatry 2001; 46:287-288.
78. Carpenter LL, Leon Z, Yasmin S, et al. Do obese depressed patients respond to topiramate? A retrospective chart review. J Affect Disord 2002; 69:251-255.
79. Woods TM, Eichner SF, Franks AS. Weight gain mitigation with topiramate in mood disorders. Ann Pharmacother 2004; 38:887-891.
80. Van Ameringen M, Mancini C, Pipe B, et al. Topiramate treatment for SSRI-induced weight gain in anxiety disorders. J Clin Psychiatry 2002; 63:981-984.
81. Canitano R. Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 2005; 27: 228-232.
82. McElroy SL, Suppes T, Keck PE Jr., et al. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. J Clin Psychiatry 2005; 66:617-624.
83. Ghaemi SN, Zablotsky B, Filkowski MM, et al. An open prospective study of zonisa-mide in acute bipolar depression. J Clin Psychopharmacol 2006; 26:385-388.
84. Wang PW, Yang YS, Chandler RA, et al. Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study. J Psychiatr Res 2008; 42:451-457.
85. Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006; 8: 175-181.
86. Streigel-Moore RH, Franko DL, May A, et al. Should night eating syndrome be included in the DSM? Int J Eat Disord 2006; 39:544-549.
87. Winkelman JW. Sleep-related eating disorder and night eating syndrome: sleep disorders, eating disorders, or both? Sleep 2006; 29:876-877.
88. Parry-Jones B, Parry-Jones WL. Pica: symptom or eating disorders? A historical assessment. Br J Psychiatry 1992; 160:341-354.
89. Rose EA, Porcerelli JH, Neale AV. Pica: common but commonly missed. J Am Board Fam Pract 2000; 13:353-358.
90. Birmingham CL, Firoz T. Rumination in eating disorders: literature review. Eat Weight Disord 2006; 11:e85-e89.
91. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Eating Disorders. 3rd. ed. Am J Psychiatry 2006; 163(July suppl):4-54.
92. Javaras KN, Pope HG Jr., Lalonde JK, et al. Co-occurance of binge eating disorder with psychiatric and medical disorders. J Clin Psychiatry 2008 (E-pub ahead of print).
93. Slof-Op’t Landt MC, van Furth EF, Meulenbelt I, et al. Eating disorders: from twin studies to candidate genes and beyond. Twin Res Hum Genet 2005; 8:467-482.
94. Jarvaris KN, Laird NM, Reichborn-Kjennerud T, et al. Familiality and heritability of binge eating disorder: results of a case-control family study and a twin study. Int J Eating Disord 2008; 41:174-179.
95. Cnattingius S, Hultman CM, Dahl M, et al. Very preterm birth, birth trauma, and the risk of anorexia nervosa among girls. Arch Gen Psychiatry 1999; 56:634-638.
96. Favaro A, Tenconi E, Santonastaso P. Perinatal factors and the risk of developing anorexia nervosa and bulimia nervosa. Arch Gen Psychiatry 2006; 63:82-88.
97. National Institute for Clinical Excellence (NICE). Eating disorders. Core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. Clinical guideline no 9. London, UK: British Psychological Society, 2004.
98. Carter WP, Hudson JI, Lalonde JK, et al. Pharmacologic treatment of binge eating disorder. Int J Eat Disord 2003; 34(suppl):S74-S88.
99. Appolinario JC, McElroy SL. Pharmacological approaches in the treatment of binge eating disorder. Curr Drug Targets 2004; 5:301-307.
100. Steffen KJ, Roerig JL, Mitchell JE, et al. Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs 2006; 11:315-336.
101. Berkman ND, Bulik CM, Brownley KA, et al. Management of eating disorders. Evidence Report/Technology Assessment No. 135. (Prepared by the RTI International-University of North Carolina Evidence-Based Practice Center under Contract no 290-02-0016.) AHRQ Publication No. 06-E010. Rockville, MD: Agency for Healthcare Research and Quality, 2006.
102. Shapiro JR, Berkman ND, Brownley KA, et al. Bulimia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40:321-336.
103. Brownley KA, Berkman ND, Sedway JA, et al. Binge eating disorder treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40:337-348.
104. Hudson JI, Pope HG Jr., Carter WP. Pharmacologic therapy of bulimia nervosa. In: Goldstein E, ed. The Management of Eating Disorders and Obesity. Totowa, NJ: Humana Press, 1999: 19-32.
105. Horne RL, Ferguson JM, Pope HG Jr.., et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988; 49:262-266.
106. Appolinario JC, Bacaltchuk J, Sichieri R, et al. A randomized, double-blind, placebocontrolled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 2003; 60:1109-1116.
107. Wilfley DE, Crow SJ, Hudson JI, et al. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multi-center placebo-controlled double-blind study. Am J Psychiatry 2008; 165:51-58.
108. Walsh BT, Kaplan AS, Attia E, et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA 2006; 296:934.
109. Bulik CM, Berkman ND, Brownley KA, et al. Anorexia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40:310-320.
110. Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003; 64:1335-1341.
111. Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 2003; 64:1449-1454.
112. Nickel C, Tritt K, Muehlbacher M, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord 2005; 38: 295-300.
113. McElroy SL, Arnold LM, Shapira NA, et al: Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160:255-261.
114. McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 2007; 61:1039-1048.
115. Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebocontrolled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 2007; 68:1324-1332.
116. McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006; 67: 1897-1906.
117. Kaplan AS, Garfinkel PE, Darby PL, et al. Carbamazepine in the treatment of bulimia. Am J Psychiatry 1983; 140:1225-1226.
118. Kaplan AS. Anticonvulsant treatment of eating disorders. In: Garfinkel PE, Garner DM, eds. The Role of Drug Treatments for Eating Disorders. New York: Brunner/Mazel, 1987: 96-123.
119. Hudson JI, Pope HG Jr. The role of anticonvulsants in the treatment of bulimia. In: McElroy SL, Pope HG Jr., eds. Use of Anticonvulsants in Psychiatry. New York, NY: Oxford Univ Press, 1988: 141-153.
120. Wermuth BM, Davis KL, Hollister LE, et al. Phenytoin treatment of binge eating syndrome. Am J Psychiatry 1977; 134:1249-1253.
121. Greenway FL, Dahms WT, Bray GA. Phenytoin as a treatment of obesity associated with compulsive eating. Curr Ther Res 1977; 21: 338-42.
122. McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry 2004; 65:1463-1469.
123. Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000; 61:368-372.
124. Schmidt do Prado-Lima PA, Bacaltchuck J. Topiramate in treatment-resistant depression and binge eating disorder. Bipolar Disord 2002; 4:271-273.
125. Felstrom A, Blackshaw S. Topiramate for bulimia nervosa with bipolar II disorders. Am J Psychiatry 2002; 159:1246-1247.
126. Barbee JG. Topiramate in the treatment of severe bulimia nervosa with comorbid mood disorders: a case series. Int J Eat Disord 2003; 33:456-472.
127. Zilberstein B, Pajecki D, Garcia de Brito AC, et al. Topiramate after adjustable gastric banding in patients with binge eating and difficulty losing weight. Obes Surg 2004; 14:802-805.
128. Guerdjikova AI, Kotwal R., McElroy SL. Response of recurrent binge eating and weight gain to topiramate in patients with binge eating disorder after bariatric surgery. Obes Surg 2005; 15:273-277.
129. Winkelman JW. Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate. Sleep Med 2003; 4:243-246.
130. Tucker P, Masters B, Nawar O. Topiramate in the treatment of comorbid night eating syndrome and PTSD: a case study. Eat Disord 2004; 12:75-78.
131. Knable M. Topiramate for bulimia nervosa in epilepsy. Am J Psychiatry 2001; 158: 322-323.
132. Guille C, Sachs G. Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:1035-1039.
133. Rosenow F, Knake S, Hebebrand J. Topiramate and anorexia nervosa. Am J Psychiatry 2002; 159:2112-2113.
134. Colom F, Vieta E, Benabarre H, et al. Topiramate abuse in a bipolar patient with an eating disorder. J Clin Psychiatry 2001; 62:475-476.
135. Chung AM, Reed MD. Intentional topiramate ingestion in an adolescent female. Ann Pharmacother 2004; 38:1439-1442.
136. McElroy SL, Kotwal R, Hudson JI, et al. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry 2004; 65:50-56.
137. Hudson JI, Pope HG Jr., Jonas JM, et al. Treatment of anorexia nervosa with antidepressants. J Clin Psychopharmacol 1985; 5:17-23.
138. Cordas TA, Tavares H, Calderoni DM, et al. Oxcarbazepine for self-mutilating bulimic patients. Int J Neuropsychopharmacol 2006; 9:769-771.
139. Stewart JT. Treatment of coprophagia with carbamazepine. Am J Psychiatry 1995; 152:295.
140. Jawed SH, Krishnan VH, Prasher VP, et al. Worsening of pica as a symptom of depressive illness in a person with severe mental handicap. Br J Psychiatry 1993; 162: 835-837.
141. Young CR, Mazure CM. Fulminant hepatic failure from acetaminophen in an anorexic patient treated with carbamazepine. J Clin Psychiatry 1998; 59:622.
142. Green RS, Rau JH. Treatment of compulsive eating disturbances with anticonvulsant medication. Am J Psychiatry 1974; 131:428-432.
143. Rau JH, Green RS. Compulsive eating: a neuropsychologic approach to certain eating disorders. Compr Psychiatry 1975; 16:223-231.
144. Rau JH, Struve FA, Green RS. Electroencephalographic correlates of compulsive eating. Clin Electroencephalogr 1979; 10:180-189.
145. Herridge PL, Pope HG Jr. Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: a case report. J Clin Psychopharmacol 1985; 5:229-230.
146. McElroy SL, Keck PE Jr., Pope HG Jr. Sodium valproate: its use in primary psychiatric disorders. J Clin Psychopharmacol 1987; 7: 16-24.
147. Tachibana N, Sugita Y, Teshima Y, et al. A case of anorexia nervosa associated with epileptic seizures showing favorable responses to sodium valproate and clonazepam. Jpn J Psychiatry Neurol 1989; 43:77-84.
148. York DA, Singer L, Thomas S, et al. Effect of topiramate on body weight and body composition of Osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 2000; 16:967-975.
149. Picard F, Deshaies Y, Lalonde J, et al. Topiramate reduces energy and fat gains in (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 2000; 8:656-663.
150. Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition 2000; 16:961-966.
151. Richard D, Picard F, Lemieux C, et al. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord 2002; 26:344-353.
152. Lalonde J, Samson P, Poulin S, et al. Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice. Physiol Behav 2004; 80:415-420.
153. Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41(suppl 1):S3-S9.
154. Kaminski RM, Banerjee M, Rogawski MA. Topiranate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004; 46:1097-1104.
155. Okada M, Kawata Y, Mizuno K, et al. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998; 124:1277-1285.
156. Ueda Y, Doi T, Tokumaru J, et al. Effect of zonisamide on molecular regulation of glutamate and GABA trasporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Re 2003; 116:1-6.
157. White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 2007; 81:85-110.
158. Stanley BG, Ha LH, Spears LC, et al. Lateral hypothalamic injections of glutamate, kainic acid, D, L-alpha-amino-3 hydroxy-5-methyl-isoxazole propionic acid or N-methyl-D-aspartic acid rapidly elicit intense transient eating in rats. Brain Res 1993; 613:88-95.
159. Zeni, LAZR, Seidler HBK, De Carvalho NAS, et al. Glutamatergic control of food intake in pigeons: Effects of central injections of glutamate, NMDA, and AMPA receptor agonists and antagonists. Pharmacol Biochem Behav 2000; 65:67-74.
160. Zheng H, Patterson C, Berthoud HR. Behavioral analysis of anorexia produced by hindbrain injections of AMPA receptor antagonist NBQX in rats. Am J Physiol Regul Integr Comp Physiol 2002; 282:R147-R155.
161. Husum H, Van Kammen D, Termeer E, et al. Topiramate normalizes hippocampal NPY-LI in flinders sensitive line ‘depressed’ rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacol 2003; 28:1292-1299.
162. Meister B. Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight. Physiol Behav 2007; 92:263-271.
163. Okada M, Hirano T, Kawata Y, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res 1999; 34:187-197.
164. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995; 22:193-205.
165. Gold MS, Star J. Eating disorders. In: Lowinson JH, Ruiz P, Millman RB, eds. Substance Abuse A Comprehensive Textbook, 2nd ed. York, Pennsylvania: Williams and Wilkins, 2004: 469-488.
166. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003; 361:1677-1685.
167. Johnson BA, Rosenthal N, Capece J, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298:1641-1651.
168. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. 2004; 75:233-240.
169. Schiffer WK, Gerasimov MR, Marsteller DA, et al. Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse 2001; 42:196-198.
170. Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo controlled study. Biol Psychiatry 2005; 57:495-499.
171. Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind placebo-controlled study. J Clin Psychiatry 2004; 65:1515-1519.
172. Nickel C, Lahman C, Tritt K, et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized double-blind, placebocontrolled study. J Affect Disord 2005; 87: 243-252.
173. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psycho-pharmacol 2005; 19:287-291.
174. Nasser JA, Gluck ME, Geliebter A. Impulsivity and test meal intake in obese binge eating women. Appetite 2004; 43:303-307.
175. McElroy S, Kotwal R. Binge eating. In: Hollander E, Stein DJ, eds. Clinical Manual of Impulse-Control Disorders. Washington, DC: American Psychiatric Publishing, 2006: 115-148.
176. Nederkoorn C, Smulders FT, Havermans RC, et al. Impulsivity in obese women. Appetite 2006; 47:253-256
177. McElroy SL, Kotwal R, Keck PE Jr., et al. Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? J Affect Disord 2005; 86: 107-127.
178. Wilkes JJ, Nguyen MT, Bandyopadhyay GK, et al. Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-fat-fed male Wistar rats. Am J Physiol Endocrinol Metab 2005; 289:E1015-E1022.
179. Liang Y, Chen X, Osborne M, et al. Topiramate ameliorates hyperglycaemia and improves glucose-stimulated insulin release in ZDF rats and db/db mice. Diabetes Obes Metab 2005; 7:360-369.
180. Wilkes JJ, Nelson E, Osborne M, et al. Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 2005; 288:E617-E624.
181. Ha E, Yim SV, Jung KH, et al. Topiramate stimulates glucose transport through AMP-activated protein kinase-mediated pathway in L6 skeletal muscle cells. Pharmacoge-nomics J 2006; 6:327-332.
182. De Simone G, Supuran CT. Antiobesity carbonic anhydrase inhibitors. Curr Top Med Chem 2007; 7:879-884.
183. Alper K, Schwartz KA, Kolts RL, et al. Seizure incidence in psychopharmacological clinical trials: an analysis of food and drug administration (FDA) summary basis of approval reports. Biol Psychiatry 2007; 62:345-354.
184. Jobe A, Lewis D, Wainwright M, et al. Three children with a syndrome of obesity and overgrowth, atypical psychosis, and seizures: a problem in neuropsychopharmacology. J Child Neurol 2000; 15:518-528.
185. Gilmour J, Skuse D, Pembrey M. Hyperphagic short stature and Prader-Willi syndrome: a comparison of behavioral phenotypes, genotypes and indices of stress. Br J Psychiatry 2001; 179:250-254.
186. Arnulf I, Zeitzer JM, File J, et al. Kleine-Levin syndrome: a systematic review of 186 cases in the literature. Brain 2005; 128:2763-2776.
187. Goscinski I, Kwiatkowski S, Polak J, et al. The Kluver-Bucy syndrome. J Neurosurg Sci 1997; 41:269-272.
188. Daousi C, Dunn AJ, Foy PM, et al. Endocrine and neuroanatomic features associated with weight gain and obesity in adult patients with hypothalamic damage. Am J Med 2005; 118:45-50.
189. Tu JB, Hartridge C, Izawa J. Psychopharmacological aspects of Prader-Willi Syndrome. J Am Acad Child Adolesc Psychiatry 1992; 31:1137-1140.
190. Smathers SA, Wilson JG, Nigro MA. Topiramate effectiveness in Prader-Willi syndrome. Pediatr Neurol 2003; 28:130-133.
191. Mukaddes NM, Kora ME, Bilge S. Carbamazepine for Kleine-Levin Syndrome. J Am Acad Child Adolesc Psychiatry 1999; 38:791-792.